Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

89.64 USD +2.37 (+2.72%)
Official Closing Price Updated: 7:33 PM EDT, Sep 23, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,018,200
Open 87.74
Bid (Size) 89.60 (1)
Ask (Size) 91.50 (6)
Prev. Close 87.27
Today's Range 87.32 - 91.82
52wk Range 43.29 - 91.82
Shares Outstanding 43,837,337
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis
-- 76% confirmed ORR in EXPLORER, with a median duration of response of 38.3 months -- 
From PR Newswire
Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Canc
-- 60% ORR in patients previously treated with vandetanib or cabozantinib, and 74% ORR in treatment-naïve patients -- 
From PR Newswire

Performance

YTD
+9.06%
+9.06%
1 Month
+19.62%
+19.62%
3 Month
+17.58%
+17.58%
6 Month
+55.41%
+55.41%
1 Year
+17.16%
+17.16%

More News

Read More
Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020
From PR Newswire
Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference
From PR Newswire
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
From PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From PR Newswire
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
From PR Newswire
CStone Pharmaceuticals Reports Financial Results for the First Half of 2020
From PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From PR Newswire
Blueprint Medicines Reports Second Quarter 2020 Financial Results
From PR Newswire
Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock Jumps
From Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.